A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

• Status: Recruiting
• Trial end date: 2024-06-13
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Gradual and progressive change in memory function reported by participants or informants for ≥ 6 months

• MMSE score of 22 to 30 (inclusive) at baseline

• CDR global score of 0.5 to 1.0 (inclusive), with a memory box score ≥0.5.

• Meet 18F flortaucipir positron emission tomography (PET) scan (central analysis) criteria

• Have a study partner who will provide written informed consent to participate

Exclusion Criteria:

• Contraindication to MRI or PET scans

• Have known allergies to LY3372689, related compounds, or any components of the formulations